Scholarlink

Objectives <p>Chemoimmunotherapy is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the survival outcomes and safety of chemoimmunotherapy in young patients with ES-SCLC.</p> Patients and methods <p>Patients with pathologically or cytologically confirmed ES-SCLC from three centers and divided into two age groups: young (aged ≤ 45 years) and control (aged &gt; 45 to ≤ 75 years) between January 2015 and December 2023. We assessed progression-free survival (PFS), overall survival (OS), and safety between the two age groups.</p> Results <p>Of the whole 347 patients, 59 were in the young group, while 288 were in the control group. The young group exhibited poorer PFS (median, 4.67 vs. 5.40 months, <i>p</i> &lt; 0.001) and OS (median, 13.7 vs. 14.4 months, <i>p</i> = 0.028) compared with the control group, particularly in the context of chemoimmunotherapy [PFS (median, 4.50 vs. 5.57 months; <i>p</i> = 0.002), OS (median, 13.20 vs. 15.33 months; <i>p</i> = 0.012), respectively]. Additionally, in the young group, chemoimmunotherapy showed similar PFS (median, 4.50 vs. 5.75 months; <i>p</i> = 0.501) and OS (median, 13.20 vs. 13.70 months; <i>p</i> = 0.508) compared to chemotherapy. Moreover, the young group had a higher incidence of immune-related adverse events (irAEs) (30.51% vs. 11.46%, <i>p</i> &lt; 0.001) and hematologic toxicity, including thrombocytopenia (25.42% vs. 14.24%, <i>p</i> = 0.033).</p> Conclusions <p>The young group had poorer survival outcomes and chemoimmunotherapy may not provide a survival benefit in young patients, as evidenced by similar PFS and OS compared to chemotherapy. Additionally, the young group also experienced a higher incidence of immune-related adverse events (irAEs) and hematologic toxicity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Efficacy and safety of first-line chemoimmunotherapy in young patients with extensive-stage small cell lung cancer: a multicenter retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月1日

查看全文
  • Lijuan Zhao,
  • Qi Xiong,
  • Yaping Long,
  • Haiming Hu,
  • Zhouhuan Dong,
  • Fengwei Zhu,
  • Jun Zhao,
  • Bo Yang,
  • Jingzhi Guan

摘要

Objectives

Chemoimmunotherapy is the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC). This study aims to evaluate the survival outcomes and safety of chemoimmunotherapy in young patients with ES-SCLC.

Patients and methods

Patients with pathologically or cytologically confirmed ES-SCLC from three centers and divided into two age groups: young (aged ≤ 45 years) and control (aged > 45 to ≤ 75 years) between January 2015 and December 2023. We assessed progression-free survival (PFS), overall survival (OS), and safety between the two age groups.

Results

Of the whole 347 patients, 59 were in the young group, while 288 were in the control group. The young group exhibited poorer PFS (median, 4.67 vs. 5.40 months, p < 0.001) and OS (median, 13.7 vs. 14.4 months, p = 0.028) compared with the control group, particularly in the context of chemoimmunotherapy [PFS (median, 4.50 vs. 5.57 months; p = 0.002), OS (median, 13.20 vs. 15.33 months; p = 0.012), respectively]. Additionally, in the young group, chemoimmunotherapy showed similar PFS (median, 4.50 vs. 5.75 months; p = 0.501) and OS (median, 13.20 vs. 13.70 months; p = 0.508) compared to chemotherapy. Moreover, the young group had a higher incidence of immune-related adverse events (irAEs) (30.51% vs. 11.46%, p < 0.001) and hematologic toxicity, including thrombocytopenia (25.42% vs. 14.24%, p = 0.033).

Conclusions

The young group had poorer survival outcomes and chemoimmunotherapy may not provide a survival benefit in young patients, as evidenced by similar PFS and OS compared to chemotherapy. Additionally, the young group also experienced a higher incidence of immune-related adverse events (irAEs) and hematologic toxicity.